Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Aug 04 2020

• By Malcolm Spicer

CBD Cannabidiol Marijuana Cannabis Time Clocks Deadline 3d Illustration

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

Related Content

FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements

Dec 28 2018

US FDA Guidance Production May Be Slowed By New OMB Review Requirement

Apr 14 2019

US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level

Mar 10 2020

US House Appropriators Request CBD Enforcement As They Ante Up $5M For FDA's Rule Development

Jul 10 2020

US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance

Jul 23 2020

Align Supplement Industry Regulation With DSHEA, Groups Tell FDA In 'Responsible Innovation' Comments

Jul 19 2019

Additional Topics

United States US States Guidance Documents Cannabidiol CBD FDA Advertising, Marketing & Sales Business Strategies Commercial Compliance Dietary Supplements Enforcement Manufacturing Policy Regulation Consumer

More from Regulation

More from Policy & Regulation

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window